Halofuginone enhances the radiation sensitivity of human tumor cell lines

Cancer Letters

Volumn 289, Issue 1, 2010, Pages 119-126

  Cook, John A ^a   Choudhuri, Rajani ^a   DeGraff, William ^a   Gamson, Janet ^a   Mitchell, James B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Fibrosis; Halofuginone; Radiation sensitizer; TGF beta

Indexed keywords

HALOFUGINONE; RADIOSENSITIZING AGENT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG MECHANISM; FIBROSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; PIPERIDINES; QUINAZOLINONES; RADIATION TOLERANCE; SIGNAL TRANSDUCTION;

EID: 75949096432     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.08.009     Document Type: Article

References (35)

1. Anscher M.S., Crocker I.R., and Jirtle R.L. Transforming growth factor-beta 1 expression in irradiated liver. Radiat. Res. 122 (1990) 77-85
2. Anscher M.S., Kong F.M., Murase T., and Jirtle R.L. Short communication: normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGF beta. Br. J. Radiol. 68 (1995) 331-333
3. Andarawewa K.L., Paupert J., Pal A., and Barcellos-Hoff M.H. New rationales for using TGFbeta inhibitors in radiotherapy. Int. J. Radiat. Biol. 83 (2007) 803-811
4. Rabbani Z.N., Anscher M.S., Zhang X., Chen L., Samulski T.V., Li C.Y., and Vujaskovic Z. Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int. J. Radiat. Oncol. Biol. Phys. 57 (2003) 563-572
5. Nishioka A., Ogawa Y., Mima T., Jin Y.J., Sonobe H., Kariya S., Kubota K., Yoshida S., and Ueno H. Histopathologic amelioration of fibroproliferative change in rat irradiated lung using soluble transforming growth factor-beta (TGF-beta) receptor mediated by adenoviral vector. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 1235-1241
6. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., Samuni A.M., Felici A., Reiss M., Yarkoni S., Sowers A., Mitchell J.B., Roberts A.B., and Russo A. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J. Biol. Chem. 279 (2004) 15167-15176
7. Anscher M.S., Thrasher B., Rabbani Z., Teicher B., and Vujaskovic Z. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int. J. Radiat. Oncol. Biol. Phys. 65 (2006) 876-881
8. Anscher M.S., Thrasher B., Zgonjanin L., Rabbani Z.N., Corbley M.J., Fu K., Sun L., Lee W.C., Ling L.E., and Vujaskovic Z. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008) 829-837
9. Liebmann J.E., Cook J.A., Fisher J., Teague D., and Mitchell J.B. In vitro studes of paclitaxel (Taxol®) as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. 86 (1994) 441-446
10. Chang J., Park K., Bang Y.J., Kim W.S., Kim D., and Kim S.J. Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res. 57 (1997) 2856-2859
11. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., and Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10 (2000) 886-895
12. Shrivastav M., De Haro L.P., and Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 18 (2008) 134-147
13. Thacker J., and Zdzienicka M.Z. The mammalian XRCC genes: their roles in DNA repair and genetic stability. DNA Repair (Amst.) 2 (2003) 655-672
14. Harari P.M., and Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin. Radiat. Oncol. 16 (2006) 38-44
15. Chinnaiyan P., Allen G.W., and Harari P.M. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin. Radiat. Oncol. 16 (2006) 59-64
16. Massague J. TGFbeta in cancer. Cell 134 (2008) 215-230
17. Flanders K.C., Sullivan C.D., Fujii M., Sowers A., Anzano M.A., Arabshahi A., Major C., Deng C., Russo A., Mitchell J.B., and Roberts A.B. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am. J. Pathol. 160 (2002) 1057-1068
18. Granot I., Halevy O., Hurwitz S., and Pines M. Halofuginone: an inhibitor of collagen type I synthesis. Biochim. Biophys. Acta 1156 (1993) 107-112
19. Pines M., and Nagler A. Halofuginone: a novel antifibrotic therapy. Gen. Pharmacol. 30 (1998) 445-450
20. Abramovitch R., Dafni H., Neeman M., Nagler A., and Pines M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1 (1999) 321-329
21. Elkin M., Miao H.Q., Nagler A., Aingorn E., Reich R., Hemo I., Dou H.L., Pines M., and Vlodavsky I. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 14 (2000) 2477-2485
22. Gavish Z., Pinthus J.H., Barak V., Ramon J., Nagler A., Eshhar Z., and Pines M. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51 (2002) 73-83
23. Abramovitch R., Itzik A., Harel H., Nagler A., Vlodavsky I., and Siegal T. Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model - an MRI study. Neoplasia 6 (2004) 480-489
24. Pines M. Targeting TGFβ signaling to inhibit fibroblast activation as a therapy for fibrosis and cancer: effect of halofuginone. Expert Opin. Drug Discov. 3 (2008) 11-20
25. McGaha T.L., Phelps R.G., Spiera H., and Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 118 (2002) 461-470
26. Chen R., Huang C., Morinelli T.A., Trojanowska M., and Paul R.V. Blockade of the effects of TGF-beta1 on mesangial cells by overexpression of Smad7. J. Am. Soc. Nephrol. 13 (2002) 887-893
27. Cordenonsi M., Dupont S., Maretto S., Insinga A., Imbriano C., and Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 113 (2003) 301-314
28. Ward I.M., and Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J. Biol. Chem. 276 (2001) 47759-47762
29. Ewald B., Sampath D., and Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Ther. 6 (2007) 1239-1248
30. Parsels L.A., Morgan M.A., Tanska D.M., Parsels J.D., Palmer B.D., Booth R.J., Denny W.A., Canman C.E., Kraker A.J., Lawrence T.S., and Maybaum J. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol. Cancer Ther. 8 (2009) 45-54
31. Marti T.M., Hefner E., Feeney L., Natale V., and Cleaver J.E. H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. Proc. Natl. Acad. Sci. USA 103 (2006) 9891-9896
32. Taras D., Blanc J.F., Rullier A., Dugot-Senant N., Laurendeau I., Bieche I., Pines M., and Rosenbaum J. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia 8 (2006) 312-318
33. Nagler A., Ohana M., Shibolet O., Shapira M.Y., Alper R., Vlodavsky I., Pines M., and Ilan Y. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur. J. Cancer 40 (2004) 1397-1403
34. de Jonge M.J., Dumez H., Verweij J., Yarkoni S., Snyder D., Lacombe D., Marreaud S., Yamaguchi T., Punt C.J., and van Oosterom A. Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur. J. Cancer 42 (2006) 1768-1774
35. Kirshner J., Jobling M.F., Pajares M.J., Ravani S.A., Glick A.B., Lavin M.J., Koslov S., Shiloh Y., and Barcellos-Hoff M.H. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 66 (2006) 10861-10869